Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 1/2 1

Status

Completed 6Terminated 5Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Terminated × tivozanib × Clear all
NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

Massachusetts General Hospital

Phase 2 Terminated
5 enrolled 8 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01673386 2020-10-27

TAURUS

AVEO Pharmaceuticals, Inc.

Phase 2 Terminated
58 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell

NCT01745367 2020-10-27

BATON-BC

AVEO Pharmaceuticals, Inc.

Phase 2 Terminated
30 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01972516 2017-06-05

Tivozanib As Maintenance Therapy In GYN

Dana-Farber Cancer Institute

Phase 2 Terminated
4 enrolled 7 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01807156 2016-04-22

Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Emory University

Phase 2 Terminated
7 enrolled 6 charts
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡